^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD276 overexpression

i
Other names: CD276, CD276 Molecule, CD276 Antigen, B7 Homolog 3, B7-H3, B7RP-2
Entrez ID:
Related biomarkers:
5d
B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma. (PubMed, Pathol Res Pract)
With clinical translational value, the predictive value of B7-H3 for conventional immunotherapy was detected using the Kaplan-Meier plotter tool, and the results showed that melanoma patients with high B7-H3 expression were insensitive to anti-PD-1 and anti-CTLA-4 immunotherapy. In conclusion, we first investigate the expression of B7-H3 in melanoma and its correlations with the TME features, and indicate B7-H3 as a promising therapeutic target in melanoma patients that are insensitive to conventional immunotherapy.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
14d
B7-H3 promotes proliferation and migration of lung cancer cells by modulating PI3K/AKT pathway via ENO1 activity. (PubMed, Transl Cancer Res)
B7-H3 directly interacts with ENO1 in lung cancer cells. B7-H3 can promote proliferation and migration of lung cancer cells by modulating PI3K/AKT pathway via ENO1 activity.
Journal
|
CD276 (CD276 Molecule) • ENO1 (Enolase 1)
|
CD276 overexpression
1m
CD276 promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma through the TGF-β/SMAD signaling. (PubMed, Clin Exp Metastasis)
CD276 is significant upregulation in ESCC tissues and facilitates the EMT process in ESCC cells via the TGF-β/SMAD signaling, thus promoting the progression of ESCC.
Journal
|
CD276 (CD276 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
|
CD276 overexpression • CD276 expression • CD2 overexpression
3ms
Effects of methionine deficiency on B7H3-DAP12-CAR-T cells in the treatment of lung squamous cell carcinoma. (PubMed, Cell Death Dis)
In conclusion, B7H3 is a prospective target for LUSC, and B7H3-DAP12-CAR-T cells are promising for LUSC treatment. Maintaining Met levels in CAR-T may help overcome TME suppression and improve its clinical application potential.
Journal • CAR T-Cell Therapy • IO biomarker
|
IFNG (Interferon, gamma) • CD276 (CD276 Molecule) • IL2 (Interleukin 2) • SLC7A5 (Solute Carrier Family 7 Member 5) • NKG7 (Natural Killer Cell Granule Protein 7)
|
CD276 overexpression
3ms
A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC. (PubMed, Oncoimmunology)
Consistently, our ELISA results verified the binding of 24F-Hu-WT and IgC1 and IgC2. Our results indicate that 24F-Hu-mut2 has significant anti-ESCC activity both in vitro and in vivo, and this monoclonal antibody may be a promising antibody against ESCC and other B7-H3 overexpressing tumors.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression
4ms
CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate (ASH 2023)
Vobra duo showed robust in vitro cytolytic activity against CD276 positive AML cells highlighting the need for ongoing preclinical evaluations of CD276 targeted therapies in AML. Given the established safety profile for vobra duo this provides a clear path for rapid translation to clinical use for high risk AML patients.
Preclinical • IO biomarker
|
KMT2A (Lysine Methyltransferase 2A) • CD276 (CD276 Molecule) • CREBBP (CREB binding protein) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KAT6A (Lysine Acetyltransferase 6A)
|
CD276 overexpression • MLL rearrangement • CD276 expression • CBFA2T3 - GLIS2 fusion • MLL fusion
|
vobramitamab duocarmazine (MGC018)
4ms
COL10A1 promotes tumorigenesis by modulating CD276 in pancreatic adenocarcinoma. (PubMed, BMC Gastroenterol)
Our research suggests that COL10A1 promotes pancreatic adenocarcinoma tumorigenesis by regulating CD276. This study provides new insight into biomarkers and possible targets for pancreatic cancer treatment.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
5ms
B7H3 increases ferroptosis resistance by inhibiting cholesterol metabolism in colorectal cancer. (PubMed, Cancer Sci)
Additionally, multiplex immunohistochemistry was carried out to show the expression of B7H3, prostaglandin-endoperoxide synthase 2, and SREBP2 in CRC tumor tissues, which was associated with the prognosis of patients with CRC. In summary, our findings reveal a role for B7H3 in regulating ferroptosis by controlling cholesterol metabolism in CRC.
Journal
|
CD276 (CD276 Molecule) • GPX4 (Glutathione Peroxidase 4) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • FTL (Ferritin Light Chain) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
|
CD276 overexpression • PTGS2 expression
5ms
Value of B7-H3 Expression as a Predictor of Response to Neoadjuvant Chemotherapy in Urothelial Cell Carcinoma of Bladder (SUO 2023)
Low level of B7-H3 expression on TURBT specimen is a predictor of complete pathologic response to neoadjuvant chemotherapy in UCB.
Clinical
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
5ms
B7H3 targeting gold nanocage pH-sensitive conjugates for precise and synergistic chemo-photothermal therapy against NSCLC. (PubMed, J Nanobiotechnology)
This study presents a dual-compartment targeted B7H3 multifunctional gold conjugate system that can precisely control Dox exposure in a spatio-temporal manner without evident toxicity and suggests a general strategy for synergistic therapy against NSCLC.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression
6ms
Generation and clinical development of an optimized B7-H3xCD3 bispecific antibody for treatment of colorectal and other gastrointestinal cancers (DGHO 2023)
Comprehensive in vitro characterization revealed that targeting the membrane-proximal epitope Q179 of the B7-H3 molecule allowed for a 100-fold reduction of CD3 affinity in our lead compound CC-3 with preserved superior tumor cell killing, efficient T cell activation, proliferation and memory formation, whereas undesired cytokine release was reduced...The trial will consist of a dose escalation part with an accelerated and a standard titration phase to determine the maximum tolerated dose followed by a dose expansion part to define the recommended phase II dose and collect first signs of efficacy. Together, we report on the straight forward development of a novel optimized bsAb from bench to first clinical evaluation that holds promise to improve treatment of CRC patients.
Clinical
|
CD276 (CD276 Molecule)
|
CD276 overexpression
|
CC-3
6ms
Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models. (PubMed, Life Sci)
Our results suggest that B7-H3-CAR-T therapy combined with radiotherapy may be a promising modality in treating solid tumors.
Preclinical • Journal • IO biomarker
|
CD276 (CD276 Molecule) • ICAM1 (Intercellular adhesion molecule 1)
|
CD276 overexpression
7ms
B7-H3 confers stemness characteristics to gastric cancer cells by promoting glutathione metabolism through AKT/pAKT/Nrf2 pathway. (PubMed, Chin Med J (Engl))
B7-H3 has a regulatory effect on GC stemness and the regulatory effect is achieved through the AKT/Nrf2/GSH pathway. Inhibiting B7-H3 expression may be a new therapeutic strategy against GC.
Journal
|
CD276 (CD276 Molecule) • CD44 (CD44 Molecule)
|
CD276 overexpression • CD276 expression • CD44 expression
7ms
ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors. (PubMed, Cancer Cell Int)
Our preclinical data indicate that ITC-6102RO is a promising therapeutic agent for B7-H3-targeted therapy. Moreover, we anticipate that OHPAS linkers will serve as a valuable platform for developing novel ADCs targeting a wide range of targets.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
8ms
Exosomal B7-H3 facilitates colorectal cancer angiogenesis and metastasis through AKT1/mTOR/VEGFA pathway. (PubMed, Cell Signal)
We found that CRC cell-drived exosomal B7-H3 was uptaken by human umbilical vein endothelial cells (HUVECs) and consequently activated the AKT serine/threonine kinase 1 (AKT1) / mechanistic target of rapamycin kinase (mTOR) / vascular endothelial growth factor A (VEGFA) signaling pathway, thus augmenting the abilities of migration, invasion and tube formation of HUVECs...Our findings reveal that CRC-derived exosomal B7-H3 promotes tumor angiogenesis and metastasis by activating the AKT1/mTOR/VEGFA signaling pathway. It provides novel insights into the roles of CRC-drived exosomes in CRC progression.
Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CD276 (CD276 Molecule)
|
CD276 overexpression
|
sirolimus
9ms
B7-H3 Associates with IMPDH2 and Regulates Cancer Cell Survival. (PubMed, Cancers (Basel))
We further demonstrate that the loss of B7-H3 in cancer cells has no effect on growth or migration in 2D but promotes the expansion of 3D spheroids in an IMPDH2-dependent manner. These findings provide new insights into the B7-H3 function in the metabolic homeostasis of normal and transformed lung cancer cells, and whilst this molecule remains an interesting target for immunotherapy, these findings caution against the use of anti-B7-H3 therapies in certain clinical settings.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule)
|
CD276 overexpression
9ms
B7-H3 Regulates Glucose Metabolism in Neuroblastom via Stat3/c-Met Pathway. (PubMed, Appl Biochem Biotechnol)
This study suggested that B7-H3 regulated the Stat3/c-Met pathway. Taken together, our data showed that B7-H3 regulates NB progression by increasing glucose metabolism in NB.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • CD276 (CD276 Molecule) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)
|
CD276 overexpression • CD276 expression
9ms
B7H3 Role in Reshaping Immunosuppressive Landscape in MSI and MSS Colorectal Cancer Tumours. (PubMed, Cancers (Basel))
Our study suggests that B7-H3 is a promising potential target for cancer therapy. Further studies must clarify the mechanisms of B7H3 overexpression and its therapeutic importance in colorectal cancer.
Journal
|
CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
10ms
The preclinical study of B7-H3 antibody in humanized mouse model (EACR 2023)
When engrafted with CT26 colon cancer cells, which stably overexpress human B7-H3 and PD-L1 while endogenous murine counterparts were knocked out, the tumor growth was inhibited certain degree by anti-B7-H3 antibody (8H9 Biosimilar, 20mpk, TGI=18.56%) treatment while inhibited significantly after the monotherapy of anti-PD-L1 (Tecentriq, 3 mpk, TGI=55.89%, p<0.001)...Analysis of tumor infiltrating lymphocytes (TILs) at the end of the efficacy study showed that the proportion of CD45+ immune cells was significantly increased in all of the treated groups. The NK cells was significantly increased and Treg cells was significantly decreased especially in the combined treatment group.ConclusionSummary, the B7-H3 and PD-L1 double humanized mouse model can be used in the pre-clinical evaluation of mono or combined immune checkpoint blockade with anti-human B7-H3 and PD-L1 therapy.
Preclinical
|
CD276 (CD276 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
CD276 overexpression
|
Tecentriq (atezolizumab)
10ms
B7-H3 but not PD-L1 is involved in the antitumor effects of Dihydroartemisinin in non-small cell lung cancer. (PubMed, Eur J Pharmacol)
Furthermore, DHA treatment led to increased infiltration of CD8 T Lymphocytes in the xenografts as compared with that of negative controls. Taken together, our results suggest that B7-H3 but not PD-L1 is involved in the antitumor effects of DHA in NSCLC, which may be indicative of an effective B7-H3 blockade and further combination with anti-PD-L1/PD-1 immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule)
|
PD-L1 overexpression • CD276 overexpression
11ms
IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer. (PubMed, Front Immunol)
Moreover, CC-3 induced efficient T cell proliferation and formation of T cell memory subsets. Together, our results emphasize the potential of CC-3, which is presently being GMP-produced to enable clinical evaluation for treatment of pancreatic, hepatic and gastric cancer.
Journal
|
IFNG (Interferon, gamma) • CD276 (CD276 Molecule)
|
CD276 overexpression
12ms
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers. (PubMed, Mol Ther)
Thus, fine-tuning of both, target and CD3 affinities as well as binding epitopes allowed for the generation of a B7-H3xCD3 bsAb with promising therapeutic activity. CC-3 is presently undergoing GMP production to enable evaluation in a clinical "first in human" study in CRC.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression
1year
B7-H3 & PD-L1 double-humanized BALB/c mouse: a novel animal model for preclinical studies of human B7-H3 antibodies or bispecific antibodies (AACR 2023)
When engrafted with CT26 colon cancer cells, which stably overexpress human B7-H3 and PD-L1 while endogenous murine counterparts were knocked out, the tumor growth was inhibited certain degree by anti-B7-H3 antibody (8H9 Biosimilar, 20mpk, TGI=18.56%) treatment while inhibited significantly after the monotherapy of anti-PD-L1 (Tecentriq, 3 mpk, TGI=55.89%, p<0.001)...Analysis of tumor-infiltrating lymphocytes (TILs) at the end of the efficacy study showed that the proportion of CD45+ immune cells was significantly increased in all of the treated groups. The NK cells were significantly increased and the Treg cells were significantly decreased especially in the combined treatment group.Based on the above, the B7-H3 and PD-L1 double humanized mouse model is suitable for the pre-clinical evaluation of mono or combined immune checkpoint blockade with anti-human B7-H3 and PD-L1 therapy.
Preclinical
|
PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
PD-L1 expression • PD-L1 overexpression • CD276 overexpression
|
Tecentriq (atezolizumab)
1year
6B5, an anti-human B7-H3 therapeutic antibody that enhances antibody-dependent cellular cytotoxicity and inhibits tumor growth in B7-H3-humanized mice (AACR 2023)
Epitope mapping revealed non-overlapping B7-H3 binding epitopes of 6B5 and Enoblituzumab. Taken together, these data suggest that 6B5 is a promising therapeutic anti-human B7-H3 IgG monoclonal antibody that may find clinical application in a range of cancers, including current refractory types.
Preclinical
|
CD276 (CD276 Molecule)
|
CD276 overexpression
|
enoblituzumab (MGA271)
1year
Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets. (PubMed, Front Immunol)
These results highlight the low or absence of mRNA levels of the canonic targetable ICs in medulloblastomas. Importantly, the analysis revealed overexpression of CD24 and CD276, which can constitute prognostic biomarkers and attractive immunotherapy targets for medulloblastomas.
Journal • PD(L)-1 Biomarker • IO biomarker
|
MSI (Microsatellite instability) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CD276 (CD276 Molecule) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD24 (CD24 Molecule) • BTLA (B And T Lymphocyte Associated) • CD48 (CD48 Molecule) • CEACAM1 (CEA Cell Adhesion Molecule 1) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • TNFSF14 (TNF Superfamily Member 14)
|
PD-L1 expression • CD276 overexpression • CD24 overexpression • CD24 expression
|
nCounter® PanCancer Immune Profiling Panel
over1year
Suppressive function of bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-187 in prostate cancer. (PubMed, Cancer Biol Ther)
Next, BMSC-exos carrying miR-187 contributed to repressed cell malignant features as well as limited tumorigenicity and tumor metastasis. Collectively, this study demonstrated that BMSC-derived exosomal miR-187 restrained prostate cancer by reducing CD276/JAK3-STAT3-Slug axis.
Journal
|
CD276 (CD276 Molecule) • JAK3 (Janus Kinase 3) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
CD276 overexpression • CD276 expression • CD2 overexpression
over1year
Anti-B7-H3 antibody (T-1A5) blocks immunomodulatory function of B7-H3 and enhances NK and T cell–mediated cytotoxicity against breast cancer cells (SABCS 2022)
Our data suggests that B7-H3 is overexpressed in primary BC and inhibits immune-cell infiltration. Moreover, blocking the immunomodulatory functions of B7-H3 using anti-B7H3 antibody T-1A5 enhances NK and T cell–mediated killing of BC cells.
IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • CD4 (CD4 Molecule)
|
HER-2 expression • CD276 overexpression • CD276 expression
over1year
ATG-027, a first-in-class B7-H3/PD-L1 bispecific antibody, shows potent T cell activation capability and in vivo anti-tumor efficacy (SITC 2022)
ATG-027 can also inhibit the interaction between PD1/PD-L1 to rescue T cell activity suppression. ATG-027’s dual T cell activation function and powerful ADCC, CDC, and ADCP properties contribute to its promising anti-tumor efficacy in preclinical models.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma) • CD276 (CD276 Molecule) • IL2 (Interleukin 2)
|
PD-L1 expression • CD276 overexpression
|
ATG-027
over1year
B7-H3 is a Checkpoint Immunotherapy Target in Advanced Prostate Cancer Harboring PTEN and TP53 Defects (SITC 2022)
Cd276 deletion also reversed the immunosuppression characterized by increased tumor-infiltrating lymphocytes. Conclusions Our studies provide the genetic evidence for the tumor-promoting and immunosuppressive role of B7-H3 in prostate cancer and offer insights into combinatorial strategies for immunotherapy targeting B7-H3 in CRPC harboring PTEN and TP53 defects.
IO biomarker
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression • TP53 expression
over1year
AML-327 Novel Anti-B7-H3 Blocking Antibody Enhances NK Cell-Mediated Cytotoxicity and Improves Outcomes in AML-Bearing Mice. (PubMed, Clin Lymphoma Myeloma Leuk)
Our data indicate that B7-H3 is overexpressed in AML and that an anti-B7-H3 antibody (T1-A5) not only blocks B7-H3's immunomodulatory function but also induces ADCC in AML cells in vitro and in vivo.
Preclinical • Journal
|
CD276 (CD276 Molecule) • CD34 (CD34 molecule)
|
CD276 overexpression • CD276 expression
over1year
Novel Anti–B7-H3 Blocking Antibody Enhances NK Cell–Mediated Cytotoxicity and Improves Outcomes in AML-Bearing Mice (SOHO 2022)
Our data indicate that B7-H3 is overexpressed in AML and that an anti–B7-H3 antibody (T1-A5) not only blocks B7-H3’s immunomodulatory function but also induces ADCC in AML cells in vitro and in vivo.
Preclinical
|
CD276 (CD276 Molecule) • CD34 (CD34 molecule)
|
CD276 overexpression • CD276 expression
over1year
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. (PubMed, Eur Urol)
The frequent overexpression of B7-H3 in CRPC compared with normal tissue and other B7 family members implicates it as a highly relevant therapeutic target in these diseases. Mechanisms driving differences in B7-H3 expression across genomic subsets warrant investigation for understanding the role of B7-H3 in cancer growth and for the clinical development of B7-H3 targeted therapies.
Journal • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • AR (Androgen receptor) • CD276 (CD276 Molecule)
|
BRCA2 mutation • CD276 overexpression • CD276 expression • AR expression
|
ifinatamab deruxtecan (DS-7300)
over1year
B7-H3 immune checkpoint molecule in prostate cancer (ECP 2022)
B7-H3 protein is overexpressed in PCa making it a promising target for immunotherapies. Examining human tissue samples, we showed an association of B7-H3 expression and aggressive clinical features, including lymph node spread. In vitro experiments with acute and chronic loss of B7-H3 revealed an effect on migration and invasion.
IO biomarker
|
CD276 (CD276 Molecule) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
|
CD276 overexpression • CD276 expression
over1year
DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study (ESMO 2022)
Conclusions DS-7300 continues to demonstrate evidence of durable antitumor activity in heavily pretreated pts with SCLC, sqNSCLC, and mCRPC. These data support further clinical development of DS-7300, including a Ph 2 dose-optimization study in SCLC (NCT05280470) with starting dose levels of 8 mg/kg and 12.0 mg/kg.
P1/2 data
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
|
ifinatamab deruxtecan (DS-7300)
over1year
Investigation of multiple immune-checkpoints in the context of the disease for personalized therapy selection (EACR 2022)
Material and Methods Spatial biomarkers characterization on tumor tissues samples from resected NSCLC (adenocarcinoma and squamous cell carcinoma) tumors treated with adjuvant pembrolizumab therapy...Conclusion Multiplexed spatial high-throughput analysis allowed to investigate at the molecular level several actors involved in immune modulation pathways responsible of drug resistance. These findings highlighted the relevance of investigating multiple biomarkers to obtain a comprehensive strategy for personalized immune therapy selection.
PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD44 (CD44 Molecule) • CD27 (CD27 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
|
CD276 overexpression • CD44 expression
|
Keytruda (pembrolizumab)
almost2years
B7 homolog 3 induces lung metastasis of breast cancer through Raf/MEK/ERK axis. (PubMed, Breast Cancer Res Treat)
Taken together, B7-H3 can promote lung metastasis in breast cancer through activation of the Raf/MEK/ERK axis.
Journal
|
CD276 (CD276 Molecule) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2)
|
CD276 overexpression • CDH1 expression • VIM expression
|
PD98059
almost2years
Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML. (PubMed, Blood)
Furthermore, treatment with ChT-1A5 in combination with human NK cells significantly prolonged survival in AML patient-derived xenograft models. Our results suggest that ChT-1A5 antibody can inhibit the immunosuppressive function of B7-H3 protein as well as induce ADCC in B7-H3+ AML.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
almost2years
Clinical Significance of the Expression of Co-Stimulatory Molecule B7-H3 in Papillary Thyroid Carcinoma. (PubMed, Front Cell Dev Biol)
This is the first comprehensive study to elucidate the expression profile of B7-H3 in PTC. Our observations revealed that B7-H3 is a novel independent biomarker for predicting LNM and disease recurrence for PTC patients, and it thus may serve as an indicator that could be used to improve risk-adapted therapeutic strategies and a novel target for immunotherapy strategies for patients who undergo an aggressive disease course.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
almost2years
LINC01123 promotes immune escape by sponging miR-214-3p to regulate B7-H3 in head and neck squamous-cell carcinoma. (PubMed, Cell Death Dis)
Notably, overexpression of LINC01123 or B7-H3 or downregulation of miR-214-3p inhibited the function of CD8T cells and promoted the progression of HNSCC. Therefore, LINC01123 acts as a miR-214-3p sponge to inhibit the activation of CD8T cells and promote the progression of HNSCC by upregulating B7-H3.
Journal
|
CD276 (CD276 Molecule) • MIR214 (MicroRNA 214)
|
CD276 overexpression